Common composition GHK-Cu, KPV, BPC-157 and TB-500 Scientific status Commercial blend name, not a recognised molecule Standard formula None officially established Direct human evidence No controlled KLOW trial identified Main evidence problem Separate studies are combined into blend-level claims TB-500 issue Frequently confused with full thymosin beta-4 UK approval No marketing authorisation identified Competitive sport Contains WADA-prohibited BPC-157 and TB-500 What Is KLOW Peptide
In September 2025, the Food and Drug Administration issued over 50 Warning Letters to companies for marketing compounded GLPs as generic versions or that make comparative claims to FDA-approved versions
Rad, P., Safari, F., Mohammadi, J
The company said soon after the FDAs announcement that it was lowering prices for the dosage levels it already offers through the site, and adding new dosage levels
B12 supports the energy metabolism that underpins all metabolic processes
